Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
AbbVie
NORTH CHICAGO, IL
NALBUPHINE HYDROCHLORIDE (nalbuphine hydrochloride) by AbbVie is clinical pharmacology mechanism of action nalbuphine is an agonist at kappa opioid receptors and an antagonist at mu opioid receptors. Approved for pain severe enough to require an opioid analgesic, for which alternative treatments are inadequate. First approved in 2024.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Mechanism of Action Nalbuphine is an agonist at kappa opioid receptors and an antagonist at mu opioid receptors. Pharmacodynamics Nalbuphine hydrochloride injection is a potent analgesic. Its analgesic potency is essentially equivalent to that of morphine on a milligram basis…
Worked on NALBUPHINE HYDROCHLORIDE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
The Evaluation of the Effectiveness and Safety of Nalbuphine Hydrochloride Injection for Analgesia in ICU Patients: A Multicenter, Randomized, Single-blinded, Parallel, Two-step Trial
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo